Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 2001 Sep 1;358(Pt 2):505–510. doi: 10.1042/0264-6021:3580505

Local and spatial factors determining HIV-1 protease substrate recognition.

S Hazebrouck 1, V Machtelinckx-Delmas 1, J J Kupiec 1, P Sonigo 1
PMCID: PMC1222085  PMID: 11513751

Abstract

Insertional mutagenesis of the Escherichia coli thymidylate synthase (TS) was used to address substrate recognition of HIV-1 protease in a well characterized structural context. By modifying the TS conformation while maintaining its enzymic activity, we investigated the influence of protein folding on protease-substrate recognition. A slight destabilization of the TS structure permitted the cleavage of a target site, which was resistant in the native TS. This result supports a dynamic interpretation of HIV-1 protease specificity. Exposure time of the potential cleavage site, which depends on the stability of the global conformation, must be compatible with the cleavage kinetics, which are determined by the local sequence. Cleavage specificity has been described as the consequence of cumulative interactions, globally favourable, between at least six amino acids around the cleavage site. To investigate influence of local sequence, we introduced insertions of variable lengths in two exposed loops of the TS. In both environments, insertion of only two amino acids could determine specific cleavage. We then inserted libraries of dipeptides naturally cleaved by the HIV-1 protease in order to assess the limitations of established classifications of substrates in different conformational contexts.

Full Text

The Full Text of this article is available as a PDF (207.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashorn P., McQuade T. J., Thaisrivongs S., Tomasselli A. G., Tarpley W. G., Moss B. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc Natl Acad Sci U S A. 1990 Oct;87(19):7472–7476. doi: 10.1073/pnas.87.19.7472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Belfort M., Maley G., Pedersen-Lane J., Maley F. Primary structure of the Escherichia coli thyA gene and its thymidylate synthase product. Proc Natl Acad Sci U S A. 1983 Aug;80(16):4914–4918. doi: 10.1073/pnas.80.16.4914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Darke P. L., Nutt R. F., Brady S. F., Garsky V. M., Ciccarone T. M., Leu C. T., Lumma P. K., Freidinger R. M., Veber D. F., Sigal I. S. HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. Biochem Biophys Res Commun. 1988 Oct 14;156(1):297–303. doi: 10.1016/s0006-291x(88)80839-8. [DOI] [PubMed] [Google Scholar]
  4. Doyon L., Croteau G., Thibeault D., Poulin F., Pilote L., Lamarre D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol. 1996 Jun;70(6):3763–3769. doi: 10.1128/jvi.70.6.3763-3769.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dunn B. M., Gustchina A., Wlodawer A., Kay J. Subsite preferences of retroviral proteinases. Methods Enzymol. 1994;241:254–278. doi: 10.1016/0076-6879(94)41068-2. [DOI] [PubMed] [Google Scholar]
  6. Farmerie W. G., Loeb D. D., Casavant N. C., Hutchison C. A., 3rd, Edgell M. H., Swanstrom R. Expression and processing of the AIDS virus reverse transcriptase in Escherichia coli. Science. 1987 Apr 17;236(4799):305–308. doi: 10.1126/science.2436298. [DOI] [PubMed] [Google Scholar]
  7. Göttlinger H. G., Dorfman T., Sodroski J. G., Haseltine W. A. Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3195–3199. doi: 10.1073/pnas.88.8.3195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hansen J., Billich S., Schulze T., Sukrow S., Moelling K. Partial purification and substrate analysis of bacterially expressed HIV protease by means of monoclonal antibody. EMBO J. 1988 Jun;7(6):1785–1791. doi: 10.1002/j.1460-2075.1988.tb03009.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hardy L. W., Finer-Moore J. S., Montfort W. R., Jones M. O., Santi D. V., Stroud R. M. Atomic structure of thymidylate synthase: target for rational drug design. Science. 1987 Jan 23;235(4787):448–455. doi: 10.1126/science.3099389. [DOI] [PubMed] [Google Scholar]
  10. Kohl N. E., Emini E. A., Schleif W. A., Davis L. J., Heimbach J. C., Dixon R. A., Scolnick E. M., Sigal I. S. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4686–4690. doi: 10.1073/pnas.85.13.4686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kunkel T. A., Roberts J. D., Zakour R. A. Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol. 1987;154:367–382. doi: 10.1016/0076-6879(87)54085-x. [DOI] [PubMed] [Google Scholar]
  12. Kupiec J. J., Hazebrouck S., Leste-Lasserre T., Sonigo P. Conversion of thymidylate synthase into an HIV protease substrate. J Biol Chem. 1996 Aug 2;271(31):18465–18470. doi: 10.1074/jbc.271.31.18465. [DOI] [PubMed] [Google Scholar]
  13. Mammano F., Petit C., Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol. 1998 Sep;72(9):7632–7637. doi: 10.1128/jvi.72.9.7632-7637.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Martinez E., Bartolomé B., de la Cruz F. pACYC184-derived cloning vectors containing the multiple cloning site and lacZ alpha reporter gene of pUC8/9 and pUC18/19 plasmids. Gene. 1988 Aug 15;68(1):159–162. doi: 10.1016/0378-1119(88)90608-7. [DOI] [PubMed] [Google Scholar]
  15. Partin K., Kräusslich H. G., Ehrlich L., Wimmer E., Carter C. Mutational analysis of a native substrate of the human immunodeficiency virus type 1 proteinase. J Virol. 1990 Aug;64(8):3938–3947. doi: 10.1128/jvi.64.8.3938-3947.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Pettit S. C., Simsic J., Loeb D. D., Everitt L., Hutchison C. A., 3rd, Swanstrom R. Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid. J Biol Chem. 1991 Aug 5;266(22):14539–14547. [PubMed] [Google Scholar]
  17. Poorman R. A., Tomasselli A. G., Heinrikson R. L., Kézdy F. J. A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base. J Biol Chem. 1991 Aug 5;266(22):14554–14561. [PubMed] [Google Scholar]
  18. Schechter I., Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun. 1967 Apr 20;27(2):157–162. doi: 10.1016/s0006-291x(67)80055-x. [DOI] [PubMed] [Google Scholar]
  19. Tomaszek T. A., Jr, Moore M. L., Strickler J. E., Sanchez R. L., Dixon J. S., Metcalf B. W., Hassell A., Dreyer G. B., Brooks I., Debouck C. Proteolysis of an active site peptide of lactate dehydrogenase by human immunodeficiency virus type 1 protease. Biochemistry. 1992 Oct 27;31(42):10153–10168. doi: 10.1021/bi00157a003. [DOI] [PubMed] [Google Scholar]
  20. Tözsér J., Weber I. T., Gustchina A., Bláha I., Copeland T. D., Louis J. M., Oroszlan S. Kinetic and modeling studies of S3-S3' subsites of HIV proteinases. Biochemistry. 1992 May 26;31(20):4793–4800. doi: 10.1021/bi00135a008. [DOI] [PubMed] [Google Scholar]
  21. Zhang Y. M., Imamichi H., Imamichi T., Lane H. C., Falloon J., Vasudevachari M. B., Salzman N. P. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol. 1997 Sep;71(9):6662–6670. doi: 10.1128/jvi.71.9.6662-6670.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES